Podcasts about roswell park

Dr. Alipi Bonm, a neuro-oncologist at the Providence Swedish Cancer Institute in Seattle, joins host Dr. Ashwani Rajput to offer up valuable insights into brain cancer, from what to expect to the promising treatment options available that could ease your fears. He also debunks common myths, such as the misconception that cell phones and electrical wires cause brain cancer and highlights promising future treatments. If you or a loved one are affected by brain cancer, discover the support groups available for both patients and caregivers. Don't miss out on this informative and supportive discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. Personalized cancer peptide vaccine shows remarkable promise against glioblastomaProvidence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancerTo learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That.We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Dr. Ankit Patel of Roswell Park on National Sunscreen Day full 225 Wed, 28 May 2025 15:22:04 +0000 1epqQ1fWTv5OvrGKs8eFrRnmwxQsSM4F news WBEN Extras news Dr. Ankit Patel of Roswell Park on National Sunscreen Day Archive of various reports and news events 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcasting.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Join us for the inaugural episode of "TWAD: Cancer, Cures and Coffee" with Dr. Ashwani Rajput and special guest Dr. Kelly Paulson. In this episode, we dive deep into the topic of Melanoma, one of the most serious types of skin cancer. Dr. Paulson, a medical oncologist at Swedish Cancer Institute First Hill in Seattle, shares her expertise on the importance of early detection, risk factors, and the latest advancements in treatment. Learn how to protect yourself and your loved ones from Melanoma and discover the role of the immune system in fighting cancer. Don't miss this informative and engaging discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. ·       Cancer survivor speaks with doctor he credits for saving his life·       Saint Patrick HealthBreak - Skin Cancers·       A year to remember: Advancements, recognition and transitions To learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That. We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Former President Joe Biden has been diagnosed with prostate cancer. Dr. Bradley Webster from Roswell Park tells us about the Gleason score, treatment and more.

April 2, 2025 - The American Cancer Society-Cancer Action Network's Michael Davoli and Roswell Park's Dr. Mary Reid advocate for legislation preventing insurers from charging out-of-pocket costs for recommended lung cancer screenings.

Dr. Andrew Storer of Roswell Park on a new nursing designation full 194 Wed, 26 Feb 2025 16:21:56 +0000 r1luqnE8rQ8wzZ1FaKrHH9eP79eSKeMZ news & politics,news WBEN Extras news & politics,news Dr. Andrew Storer of Roswell Park on a new nursing designation Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcas

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. And it most commonly impacts older adults, with higher prevalence among men and African Americans. What are the symptoms and signs that are often subtle or overlooked, leading to delays in diagnosis? What treatment options are available for those diagnosed? In this episode spoke with Jens Hillengass, MD, PhD, chief of the Myeloma and Amyloidosis Service and vice chair of research of the Department of Medicine at Roswell Park Cancer Institute about the importance of early detection, healthy lifestyle strategies, and recent advances in research that offer hope. We then sat down with Jacqueline Henry, BSN, RN, nurse manager for the lymphoma and myeloma department at Roswell Park, about what quality of life looks like for patients, treatment goals, and how to find hope after diagnosis.

President and CEO of Roswell Park Comprehensive Cancer Center, Dr. Candace Johnson on Sunday's Big Game commercial, "What Matters Most" full 183 Thu, 06 Feb 2025 18:15:55 +0000 EDKk9jNmtuO0gF03eSNytPOSbBGT9Rlv buffalo,news,super bowl lix,roswell park comprehensive cancer center,wben WBEN Extras buffalo,news,super bowl lix,roswell park comprehensive cancer center,wben President and CEO of Roswell Park Comprehensive Cancer Center, Dr. Candace Johnson on Sunday's Big Game commercial, "What Matters Most" Archive of various reports and news events 2024 © 2021 Audacy, Inc. News

Roswell Park's Dr. Rikki Cannioto on the Surgeon General's call for warning labels on alcoholic products full 345 Mon, 06 Jan 2025 09:00:20 +0000 e4iy0T87eL6cJRzC2MOF6kMOCqiUrspG news & politics,news WBEN Extras news & politics,news Roswell Park's Dr. Rikki Cannioto on the Surgeon General's call for warning labels on alcoholic products Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False

We love to hear from our listeners. Send us a message.Cell & Gene: The Podcast Host Erin Harris talks to Christopher Choi, Ph.D., MBA, SVP Industry Partnership, Director of GMP and Cell Manufacturing Facility, and Associate Professor of Oncology at Roswell Park Comprehensive Cancer Center about the Center's Buffalo, NY-based cell and gene therapy hub slated to open in early 2025. They cover the increasingly important role of automation and digital technologies in CGT manufacturing. Choi also offers his advice to new and emerging CGT biotechs on how to correctly tackle manufacturing as they begin their product development journey. Email Erin at erin.harris@cellandgene.com with topics you'd like us to cover in future episodes. Subscribe to the podcast!Apple | Spotify | YouTube

New York Gov. Kathy Hochul celebrates the openingof the state's first cell and gene therapy hub at Roswell Park Comprehensive Cancer Center in Buffalo full 2840 Mon, 16 Dec 2024 16:00:24 +0000 RzAzEc7F6TrUAY3EAsj1X1XPZpfe1I8N buffalo,news,kathy hochul,roswell park comprehensive cancer center,new york state,wben WBEN Extras buffalo,news,kathy hochul,roswell park comprehensive cancer center,new york state,wben New York Gov. Kathy Hochul celebrates the openingof the state's first cell and gene therapy hub at Roswell Park Comprehensive Cancer Center in Buffalo Archive of various reports and news events 2024 © 2021 Audacy, Inc. News

Host Emily Walsh Martin, PhD, is joined by Chris Choi, PhD, Roswell Park Comprehensive Cancer Center's Senior Vice President of Industry Partnerships and Technical Director of the center's new Good Manufacturing Practice (cGMP) Facility. Dr. Choi is also an associate professor of oncology. This wide-ranging conversation covers cell therapy development and manufacturing and how the growing Roswell Park Center is aiming to support sponsors in the CAR T and cell therapy space. Emily and Chris also discuss their experiences on cross-functional teams and how a program's research, manufacturing, and clinical elements must be knit together for success. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Mike and Bulldog break down all the news in the AFC and are joined by Trysta Krick

12pm - Live at Roswell Park recapping the Sabres win over the Dallas Stars

12:30pm - Live from Roswell Park with the VP of patient care experience joins the show

Roswell Park receives federal funding for State-of-the-Art Biobank full 286 Wed, 09 Oct 2024 15:46:59 +0000 bER1Sj6fzwS9vAqxYJqyYZi7hYGrLwcH news & politics,news WBEN Extras news & politics,news Roswell Park receives federal funding for State-of-the-Art Biobank Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepo

Roswell Park receives federal funding for a new State-of-the-Art Biobank full 286 Wed, 09 Oct 2024 15:55:11 +0000 EaJNwVnwLPO4PBNvS55YW39IDjWETJPZ news & politics,news WBEN Extras news & politics,news Roswell Park receives federal funding for a new State-of-the-Art Biobank Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.ampe

Roswell Park's Dr. Kim Brady on basal cell carcinoma, which Gov. Hochul announced Thursday she'll get treatment for full 281 Thu, 12 Sep 2024 18:49:13 +0000 J7wHEputg7727exfiiHCZupdLsKFtHUQ news & politics,news WBEN Extras news & politics,news Roswell Park's Dr. Kim Brady on basal cell carcinoma, which Gov. Hochul announced Thursday she'll get treatment for Archive of various reports and news events 2024 © 2021 Audacy, Inc.

On this episode of the Club + Resort Talks podcast, Rob Thomas, Editor-in-Chief of Club + Resort Business, chats with Brock Orlowski, MBA, CDORS, USPTA Elite, PPR, Director of Racquet Sports at Fort Wayne (Ind.) Country Club. The two talk about everything from growing the racquets industry through The Directors' Club of America and the inaugural Directors' Club Retreat, to cultivating the rapidly growing interest in racquet sports—pickleball, tennis, padel, and more. Rob and Senior Editor Phil Keren also discussed some innovative projects and events happening at golf courses around the country. Canal Shores golf course in Evanston, Ill. will now be known as The Evans at Canal Shores, offering a connection to the namesake of the Evans Scholars Foundation, Chick Evans. The new golf course will re-open in 2025 with an upgraded par-60, 18-hole golf course, youth development training center and Western Golf Association Caddie Academy. Evans attended high school in Evanston and became a great amateur golfer. Instead of turning professional, Evans worked with the Western Golf Association to use the earnings from his golf career to establish the Evans Scholars Foundation in 1930. Wanakah Country Club in Hamburg, N.Y. recently hosted its ninth annual golf marathon. This year's event teed off at 5:20 a.m. and included 28 players who played and walked 100 holes of golf in the one-day tournament. The event, known as “The Walk Fore Luca & Carly,” benefits Roswell Park's Courage of Carly Fund for programs supporting pediatric cancer patients and their families, and Live Like Luca, the Luca S. Calanni Foundation. A proposed short course at the Stanwich Club in Greenwich, Conn. and The Loop Golf Course in Chaska, Minn., showcase innovations that cater to diverse golfing needs and abilities. Stanwich Club's short course, named “The Cauldron,” offers a quicker game with about half the number of holes of a standard 18-hole course. This format is designed for those looking to improve their skills or enjoy a faster round of golf. The Loop Golf Course in Chaska, Minn. has emerged as a groundbreaking facility designed with wheelchair users in mind. This 9-hole, par-28 course, created through a partnership between the city of Chaska and Barrier Free Golf, eliminates traditional barriers such as sand traps and rough terrain to ensure accessibility for all players.

12pm Hour 2: Talking with co-founder of the 11 Day Power Play helping Roswell Park.

12:30pm Hour 2: Derek gives shout outs to the people that will be involved in the 11 Day Power Play.

1pm Hour 3: Derek and Brayton talk about team WGR for the 11 Day Power Play

Hour 3 in full

Roswell Park earns 'Exceptional' Rating from National Cancer Institute With Best-Ever Core Grant

Get ready to tap into the latest buzz in Buffalo's beer scene with our April events roundup! In this episode, we're serving up a frothy mix of exciting happenings, from collaborative brew festivals to new beer releases and taproom openings.First up, mark your calendars for the fourth annual CollaBEERation Festival at the Powerhouse on April 13th. Join the Buffalo Beer Geeks community as they team up with 48 local breweries, cideries, and meaderies to craft never-before-tasted libations. Plus, this year's event comes with a pro wrestling twist, so don't forget to don your favorite wrestler attire!Then, we're diving into the haze craze with Pressure Drop Brewing's latest release, Super Silver Haze IPA. With its bright bouquet of orange blossom and mandarin orange flavors, it's the perfect brew for celebrating 4/20 in style.But that's not all! Buffalo Restaurant Week is back from April 15th to 21st, showcasing the best of the city's culinary and craft beer scene. From Big Ditch Brewing to Clarksburg Cider, join us as we explore the delicious deals and signature dishes on offer.And speaking of collaborations, Resurgence Brewing is teaming up with OnCore Golf and PGA Hope WNY once again for the return of Smash Factor IPA. Swing by on April 13th for the release party, featuring putting games, giveaways, and a chance to support WNY PGA Hope with every pint purchased.In other news, Steel Leaf Brewing is set to open its doors on Hertel Avenue, bringing a new hub for beer enthusiasts to gather and explore experimental brews. Plus, don't miss out on Thawfest at Riverworks on April 26th, where you can sample a wide array of spring-inspired brews while supporting local charities.And finally, score yourself a free Resurgence Brewing pint glass at Consumers Beverages with the purchase of two 4-packs of their 391 IPA. It's a win-win, with proceeds going to support Ryan's Fund and the Courage of Carly Fund at Roswell Park.So grab your favorite brew, tune in, and join us as we raise a glass to all the hoppy happenings in Buffalo this April!

Dr. Bradley Webster of Roswell Park on the importance of getting tested for prostate cancer

5:45pm Hour 3 - Mike and Bulldog are joined by Dr. Shernan Holtan to talk what goes on at Roswell Park and bringing awareness to get screened. 

Today's program is very education-centric. Beginning with the layoffs of 16 teachers in the Hamburg School District, what do you make of this? And general, how has education changed over the years? Also, hear from Steven Nurkin of Roswell Park about the rise of cancer diagnoses in young adults.

8:45 Hour 3 - Dr. Brentjens joins the guys to talk to them about the importance of cancer screenings and also some of the work that goes into cancer research. 

10:45am Hour 1 - Dr. Betts joins the show to talk to Sal about the importance of getting screened for cancer. 

Dr. Shipra Gandhi, Roswell Park, on participating in a new breast cancer vaccine trial

Brian and Marty welcome Kim Sweeny of Roswell Park to talk about the impact of Hockey Fights Cancer.

PRESSURE DROP BREWING IS UP FOR SALEPressure Drop Brewing is now on the market. The sale includes the operation, equipment and furnishings at its two locations in Buffalo, including the brewery on Vandalia St. and the pub on Elmwood Ave. Inquiries can be submitted via pressuredropbrewers.com/news.CELEBRATE NATIONAL IPA DAY AT ELI FISH BREWING AND SOUTHERN TIER BREWINGAugust 3 marks National IPA Day and a number of local breweries are celebrating, including Eli Fish in Batavia and Southern Tier in Buffalo. The latter will offer $10 IPA flights and $5 IPA crowlers all day long beginning at 11am on Aug. 3, and the former will release a new hazy IPA – The Greatest Of All Warriors, a double dry hopped New England IPA with Rakau and Motueka hops, on Aug. 2. It will be available on draft and in cans to go.BUFFALO BREWING CELEBRATES 7THANNIVERSARY THIS WEEKENDThis Saturday, July 29 marks the seventh anniversary of Buffalo Brewing Company and the brewery is celebrating with beer, deep dish pizza from Buffalo Deep Dish, live music from Community Service (2pm) and exclusive merch raffles. FROTH BREWING TEAMS WITH BUFFALO RAPPER ON NEW BEERFroth Brewing has teamed up with Buffalo's own, Def Jam Recording artist Benny the Butcher, on Coconut Key Lime Pie, a new heavily fruited sour ale.CELEBRATE CHRISTMAS IN JULY AT SAD BOYS BREWINGWhile July may soon be over, there is still time to celebrate Christmas in July and what better place to do so than at Sad Boy Brewing. Bring the entire family on July 29 as none other than Santa Claus will be at the brewery (1-4pm). All night (1-11pm) there will be Christmas music playing, an Ugly Sweater Competition takes place at 9pm and all day long, $1 from every pint sold in the taproom will be donate to Roswell Park.HOFBRAUHAUS HOFBRAU KELLER TAPPING WITH BUFFALO BEER LEAGUEHofbrauhaus will debut their newest summer seasonal, Hofbrau Keller, on August 3 (6pm) with help from the Buffalo Beer League, who will serve as celebrity keg tappers for the event. Members of the BBL will lead the ceremonial parade and then will help to tap the keg of Hofbrauhaus' newest lager. Keller is 5.1%, is brewed with Herkules, Perle, Magnum, and Select hops, and features a hoppy aroma, touch of fruitiness, and a refreshing, subtle hoppy finish. Die Haus Band will take the stage at 6pm. All guests in attendance, 21+, will receive a complimentary Keller after the tapping. For reservations, please visit www.hofbrauhausbuffalo.com or call (716) 939-2337.AUGUST IS HOPFEST AT FLYING BISON BREWINGWhile National IPA Day is August 3, Flying Bison Brewing is celebrating the believed beer style all month long as the entire month of August is Hopfest, which will feature IPAs on draft and in cans. The hoppy selection is led by newer offerings, Hazy Chain Pineapple Double IPA (big, hazy and smooth with a slight nose of pineapple) and Down By the River IPA (Belgian style IPA featuring Cascade, Chinook, Centennial and Idaho 7 hops fermented with Belgian Ardennes yeast), and also features hoppy brews such as HopCat IPA, Jucie Caboose and DubMaster DDH IPA, on draft. The brewery will also have their Buffalo Kush DIPA in cans (big hop rush featuring Simcoe, Mosaic and Columbus hops). Hosted on Acast. See acast.com/privacy for more information.

Hour 2: Team WGR played in the 11 Day Power Play and hit their $10 million goal!

Hour 2: Live update on Jeremy's 100 Holes of Golf

Hour 2: Jeremy White hops on the show as he continues his 100 Holes of Golf

Hour 2: 100 Holes of Golf begins tomorrow

Hour 4: Jeremy saddling up for the Ride for Roswell this weekend and 100 Holes of Golf coming up

Hour 4: Jeremy gets set for 100 Holes of Golf a week away

Hour 4: The 11 Day Power Play begins today and look to hit their $10 million goal

Hour 4: Cancer survivor Tom Frizzell joins the show on his first time doing 100 holes of gold  

Hour 4 in full

Carla Dannug Linkedin Education- Loyola University-Nursing Chamberlain University-MSN-FNP-